Pharmacokinetics of CC-90001 in Hepatic Impairment

Phase 1, open-label trial of CC-90001 in idiopathic pulmonary fibrosis (IPF) (5 arms), sponsored by Celgene Corporation. Primary endpoints: Area Under the Plasma Concentration-Time Curve from Time Zero to Time t up to 7 days, Area Under the Plasma Concentration-Time Curve from Time Zero to Infinity up to 7 days and 5 more. Started Dec 2018; status: completed.